IN2014MN01495A - - Google Patents
Info
- Publication number
- IN2014MN01495A IN2014MN01495A IN1495MUN2014A IN2014MN01495A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A IN 1495MUN2014 A IN1495MUN2014 A IN 1495MUN2014A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A
- Authority
- IN
- India
- Prior art keywords
- metal
- formula
- group
- mixed
- patient
- Prior art date
Links
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004696 coordination complex Chemical class 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 229910052723 transition metal Inorganic materials 0.000 abstract 2
- 150000003624 transition metals Chemical class 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
- C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1234A mixed metal complex of a compound of Formula I or a salt thereof wherein the mixed metals comprise a Group III XII transition metal and a Group II metal: (Formula I) (I) wherein X R R R and R are as defined herein is produced in a one step crystallization from a solution of the Group III XII transition metal the Group II metal and a compound of Formula I. Methods for treatment of a pathological condition in a patient for example a pathological condition caused by the presence of oxygen derived free radicals comprises administering the mixed metal complex to the patient.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261583377P | 2012-01-05 | 2012-01-05 | |
| US201261656178P | 2012-06-06 | 2012-06-06 | |
| US201261668679P | 2012-07-06 | 2012-07-06 | |
| US201261721575P | 2012-11-02 | 2012-11-02 | |
| PCT/IB2012/056959 WO2013102806A1 (en) | 2012-01-05 | 2012-12-04 | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01495A true IN2014MN01495A (en) | 2015-04-17 |
Family
ID=47559596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1495MUN2014 IN2014MN01495A (en) | 2012-01-05 | 2012-12-04 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9187509B2 (en) |
| EP (1) | EP2800755B1 (en) |
| JP (2) | JP6131271B2 (en) |
| KR (1) | KR102086022B1 (en) |
| CN (2) | CN107353313B (en) |
| AU (1) | AU2012364227B2 (en) |
| BR (1) | BR112014016497B1 (en) |
| CA (1) | CA2862736C (en) |
| ES (1) | ES2683038T3 (en) |
| HK (1) | HK1245276B (en) |
| IN (1) | IN2014MN01495A (en) |
| MX (1) | MX2014008247A (en) |
| RU (2) | RU2622646C2 (en) |
| WO (1) | WO2013102806A1 (en) |
| ZA (1) | ZA201404904B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014MN01495A (en) * | 2012-01-05 | 2015-04-17 | Pledpharma Ab | |
| US20150313921A1 (en) * | 2012-11-02 | 2015-11-05 | Pledpharma Ab | Cancer Treatment Methods |
| US10233205B2 (en) | 2015-08-07 | 2019-03-19 | Auburn University | Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species |
| EP3402475B1 (en) | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| JP7065866B2 (en) * | 2016-11-14 | 2022-05-12 | カールソン－タナー インベスト エーエス | Use of non-transition metal-coordinated dipyridoxyl compounds to prevent and treat chemotherapy-induced PSN |
| KR102843447B1 (en) | 2021-05-18 | 2025-08-06 | 가부시키가이샤 엘티티 바이오파마 | Pharmaceutical composition for treating or preventing disorders accompanying the administration of anticancer drugs |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091169A (en) | 1987-05-08 | 1992-02-25 | Salutar, Inc. | Dipyridoxyl phosphate NMRI contrast agent compositions |
| US5223243A (en) | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| AR246956A1 (en) | 1987-05-08 | 1994-10-31 | Salutar Inc | Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents |
| US5403834A (en) | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| EP1060174B1 (en) | 1997-12-23 | 2004-09-22 | Amersham Health AS | Nitric oxide releasing chelating agents and their therapeutic use |
| FR2823977B1 (en) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | USE OF MANGAFODIPIR IN THE TREATMENT OF THE EFFECTS OF OXIDATIVE STRESS |
| DE10359628A1 (en) | 2003-12-18 | 2005-07-21 | Oxeno Olefinchemie Gmbh | Catalyst and process for the preparation of 1-olefins from 2-hydroxyalkanes |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| CA2708113C (en) | 2007-12-14 | 2017-08-22 | Pledpharma Ab | Compounds for use in the treatment of cancer |
| US8414866B2 (en) * | 2007-12-17 | 2013-04-09 | Ge Healthcare As | Method of magnetic resonance imaging of the heart with paramagnetic MN2+ |
| MX336359B (en) * | 2009-07-06 | 2016-01-15 | Pledpharma Ab | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound. |
| IN2014MN01495A (en) * | 2012-01-05 | 2015-04-17 | Pledpharma Ab |
-
2012
- 2012-12-04 IN IN1495MUN2014 patent/IN2014MN01495A/en unknown
- 2012-12-04 MX MX2014008247A patent/MX2014008247A/en active IP Right Grant
- 2012-12-04 CN CN201710588057.1A patent/CN107353313B/en active Active
- 2012-12-04 ES ES12815799.7T patent/ES2683038T3/en active Active
- 2012-12-04 KR KR1020147021727A patent/KR102086022B1/en not_active Expired - Fee Related
- 2012-12-04 EP EP12815799.7A patent/EP2800755B1/en active Active
- 2012-12-04 CN CN201280070691.1A patent/CN104169291B/en active Active
- 2012-12-04 RU RU2014132184A patent/RU2622646C2/en active
- 2012-12-04 CA CA2862736A patent/CA2862736C/en active Active
- 2012-12-04 AU AU2012364227A patent/AU2012364227B2/en active Active
- 2012-12-04 JP JP2014550770A patent/JP6131271B2/en active Active
- 2012-12-04 RU RU2017119660A patent/RU2765805C2/en active
- 2012-12-04 WO PCT/IB2012/056959 patent/WO2013102806A1/en not_active Ceased
- 2012-12-04 BR BR112014016497-5A patent/BR112014016497B1/en active IP Right Grant
- 2012-12-04 US US14/369,153 patent/US9187509B2/en active Active
-
2014
- 2014-07-02 ZA ZA2014/04904A patent/ZA201404904B/en unknown
-
2015
- 2015-10-26 US US14/922,555 patent/US9597334B2/en active Active
-
2017
- 2017-02-28 US US15/445,588 patent/US10111893B2/en active Active
- 2017-04-17 JP JP2017081176A patent/JP6316479B2/en active Active
-
2018
- 2018-04-04 HK HK18104469.4A patent/HK1245276B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| PH12015502839A1 (en) | Antiviral compounds | |
| EA201301154A1 (en) | BRANCHED DERIVATIVES OF 3-PHENYL-PROPICIC ACID AND THEIR APPLICATION | |
| MX362060B (en) | Antiviral compounds inhibitors of hcv ns5b. | |
| IN2014MN01495A (en) | ||
| MX2014001180A (en) | Nuclear transport modulators and uses thereof. | |
| PH12015501316A1 (en) | Heterocyclic compound | |
| MX352928B (en) | Pyridazine amide compounds and their use as syk inhibitors. | |
| MY170262A (en) | Dicarboxylic acid compound | |
| MX2014011921A (en) | Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof. | |
| MX2014002936A (en) | Novel betulinic acid derivatives with antiviral activity. | |
| MX361458B (en) | Pyrimido- pyridazinone compounds and use thereof. | |
| NZ711343A (en) | Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation | |
| MY170637A (en) | Macrocyclic compound and methods for its production | |
| MX2013008340A (en) | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer. | |
| IN2014CN04449A (en) | ||
| GEP20166448B (en) | Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate | |
| IN2012DN05192A (en) | ||
| MX351863B (en) | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof. | |
| MX349548B (en) | Thienopyrimidine compounds. | |
| MX357763B (en) | Treatment for pancreatic cancer. | |
| JO3196B1 (en) | Process for the preparation of the l-arginine salt of perindopril | |
| MX2012004914A (en) | 2-aminoindole compounds and methods for the treatment of malaria. | |
| TH149370A (en) | Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment |